

Human lymphoblastoid interferon antigen prodn. - by treating N-terminal peptide of human lymphoblastoid interferon and deriv. in presence of heptene carrier bonding reagent

Patent Assignee: OTSUKA PHARM CO LTD

Patent Family Patent Number Kind Date Application Number Kind Date Week Type

JP 58035122 A 19830301 JP 81133125 A 19810824 198314 B

JP 89060040 B 19891220 199003

Priority Applications (Number Kind Date): JP 81133125 A ( 19810824)

Patent Details Patent Kind Language Page Main IPC Filing Notes

JP 58035122 A 25

#### Abstract:

JP 58035122 A

Antigen is produced by treating N-terminal peptide of human lymphoblastoid interferon (I) of formula

R-Leu-Ile-Leu-Leu-Ala-Gln-OH

(R is H, H-Thr-His-Ser-Leu-Gly -Asn-Arg-Arg-Ala, H-Ser-Asp-Leu-Pro-Gln-Thr -His-Ser-Leu-Gly-Asn -Arg-Arg-Ala, or H-Tyr-Ser-Asp-Leu-Pro-Gln -Thr-His-Ser-Leu-Gly -Asn-Arg-Arg-Ala) and at least one kind of its deriv. with carrier in the presence of heptene-carrier bonding reagent to give human lymphoblastoid interferon antigen.

New antibody for isolation-purificn. of human alpha-type interfere interferon, partic., lymphoblastoid interferon, antigen for the prodn. of the antibody and heptene suitable for prodn. of the antigen are also described. Certain human lymphoblastoid interferon N-terminal peptide and its derivs. are used producing new human lymphoblastoid interferon antigens. The antigen is used to produce new antibody having specificity to human lymphoblastoid interferon. This antibody is used in affinity chromatography and end human alpha-type of interferon may be purified.

excellent human lymphoblastoid interferon specificity and determin. of human lymphoblastoid interferon may be effected with high precision. The antibody is labelled with enzyme on fluorecent substance and may be used in Enzyme immunoassay (ETA) method. Fluorescence immunoassay

Derwent World Patents Index

© 2004 Derwent Information Ltd. All rights reserved.

Dialog® File Number 351 Accession Number 3673742